StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. logo

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

300760 · XSHE · Medical Devices · China

Book Value Growing 3yFcf Positive 3yLow Vol 1yOpcf Growing 3yProfitable 3yRevenue Growing 3y
Market Capitalization212.08B CNY
Trailing P/E24.60 CNY
52-Week Change-39.48 CNY
Forward Annual Dividend Yield1.54%
Beta0.3050 CNY

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a prominent player in the medical technology arena, specializing in the development and manufacturing of advanced medical devices. The company's primary function is to create state-of-the-art biomedical electronics that enhance clinical diagnostics and patient care. Mindray is renowned for its comprehensive product portfolio, which includes patient monitoring systems, in-vitro diagnostics, and medical imaging systems. These products serve crucial roles in various healthcare sectors, such as hospitals, outpatient care, and emergency services, ensuring efficient and accurate medical interventions. Established in Shenzhen, China, the firm has expanded its reach globally, making significant strides in both developing and developed markets. Mindray's commitment to innovation and quality positions it as a leader in the critical mission of empowering healthcare providers with reliable diagnostic tools. Within the financial markets, Mindray is recognized for its robust growth and strategic market presence, reflecting its essential contribution to the evolving landscape of global healthcare solutions.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
212.08BCNY
NormalMar 18, 2026
Trailing P/E
24.60CNY
NormalMar 18, 2026
Revenue (TTM)
33.07BCNY
NormalMar 18, 2026
Profit Margin
26.01%
NormalMar 18, 2026
Beta
0.3050CNY
NormalMar 18, 2026
52-Week Change
-39.48CNY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
1.54%
NormalMar 18, 2026
Forward Yield
1.54%
Below 5Y avg (1.81%)
Annual Rate
CNY 2.70
Paid semi-annual
Payout Ratio
69.4%
Moderate
Loading dividend history...

Track Record

Frequency
Semi-Annual
Payback Period
61.2 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Nov 12, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
212.08BCNY
NormalMar 18, 2026
Enterprise Value
203.61BCNY
NormalMar 18, 2026
Trailing P/E
24.60CNY
NormalMar 18, 2026
Forward P/E
18.88CNY
NormalMar 18, 2026
PEG Ratio
18.88CNY
ExtremeMar 18, 2026
Price to Sales (TTM)
6.41CNY
NormalMar 18, 2026
Price to Book (MRQ)
5.39CNY
NormalMar 18, 2026
Enterprise to Revenue
6.16CNY
NormalMar 18, 2026
Enterprise to EBITDA
18.75CNY
NormalMar 18, 2026
Profitability & Growth60
Gross Margin
60.84%
NormalMar 18, 2026
Profit Margin
26.01%
NormalMar 18, 2026
Operating Margin
35.65%
NormalMar 18, 2026
Return on Assets (TTM)
0.0988CNY
NormalMar 18, 2026
Return on Equity (TTM)
0.2052CNY
NormalMar 18, 2026
Revenue (TTM)
33.07BCNY
NormalMar 18, 2026
Revenue per Share (TTM)
27.31CNY
NormalMar 18, 2026
Quarterly Revenue Growth
0.0150CNY
NormalMar 18, 2026
Gross Profit (TTM)
19.84BCNY
NormalMar 18, 2026
EBITDA
10.94BCNY
ExtremeMar 18, 2026
Net Income (TTM)
8.60BCNY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
-0.1870CNY
NormalMar 18, 2026
Operating Cash Flow (TTM)
8.63BCNY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
3.74BCNY
NormalMar 18, 2026
Forward Annual Dividend Rate
2.70CNY
NormalMar 18, 2026
Forward Annual Dividend Yield
1.54%
NormalMar 18, 2026
Trailing Annual Dividend Rate
2.66CNY
NormalMar 18, 2026
Trailing Annual Dividend Yield
1.52%
NormalMar 18, 2026
5-Year Average Dividend Yield
181.00%
ExtremeMar 18, 2026
Payout Ratio
0.6941CNY
NormalMar 18, 2026
Minority Interest (Equity)
4.90B
NormalFY2024 · Dec 31, 2024
Revenue
36.73B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
13.55B
NormalFY2024 · Dec 31, 2024
Gross Profit
23.18B
NormalFY2024 · Dec 31, 2024
Operating Income
13.05B
NormalFY2024 · Dec 31, 2024
Pre-tax Income
13.02B
NormalFY2024 · Dec 31, 2024
Income Tax Expense
1.28B
NormalFY2024 · Dec 31, 2024
Net Income
11.74B
NormalFY2024 · Dec 31, 2024
EBIT
13.02B
NormalFY2024 · Dec 31, 2024
ebitda-income
14.90B
NormalFY2024 · Dec 31, 2024
Research & Development
3.67B
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
1.72B
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
400.54M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
557.48M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
853.64K
NormalFY2024 · Dec 31, 2024
EPS (Basic)
9.64
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
9.63
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
1.21BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
1.21BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
11.74B
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
-71.48M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
10.30B
NormalFY2024 · Dec 31, 2024
Free Cash Flow
10.47B
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
14.91B
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
11.74B
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
131.82M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-347.15M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
-1.22B
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-1.93B
NormalFY2024 · Dec 31, 2024
Net Acquisitions
-5.77B
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-1.11B
NormalFY2024 · Dec 31, 2024
Sale of Investments
1.33B
NormalFY2024 · Dec 31, 2024
Other Investing Activity
101.82M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-7.38B
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
2.64M
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-5.50M
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-8.74B
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-35.45M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-8.78B
NormalFY2024 · Dec 31, 2024
Financial Strength30
Shares Outstanding
1.21BShares
NormalMar 18, 2026
Float Shares
521.58MCNY
NormalMar 18, 2026
% Held by Insiders
0.5539CNY
NormalMar 18, 2026
% Held by Institutions
0.1655CNY
NormalMar 18, 2026
Total Cash (MRQ)
17.52BCNY
NormalMar 18, 2026
Total Cash per Share (MRQ)
14.45CNY
NormalMar 18, 2026
Total Debt (MRQ)
358.61MCNY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
0.8110CNY
NormalMar 18, 2026
Current Ratio (MRQ)
2.54CNY
NormalMar 18, 2026
Book Value per Share (MRQ)
32.43CNY
NormalMar 18, 2026
Total Assets
56.64B
NormalFY2024 · Dec 31, 2024
Total Current Assets
25.65B
NormalFY2024 · Dec 31, 2024
Total Liabilities
15.89B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
31.00B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
5.46B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
10.43B
NormalFY2024 · Dec 31, 2024
Cash
16.43B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
0.00
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
16.64B
NormalFY2024 · Dec 31, 2024
Accounts Receivable
3.22B
NormalFY2024 · Dec 31, 2024
Inventory
4.76B
NormalFY2024 · Dec 31, 2024
Accounts Payable
2.79B
NormalFY2024 · Dec 31, 2024
Short-term Debt
120.83M
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
420.18M
NormalFY2024 · Dec 31, 2024
Long-term Debt
177.66M
NormalFY2024 · Dec 31, 2024
Other Non-current Liabilities
1.05B
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
1.21B
NormalFY2024 · Dec 31, 2024
Retained Earnings
27.62B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
40.76B
NormalFY2024 · Dec 31, 2024
Treasury Stock
337.77M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
174.24CNY
NormalMar 18, 2026
52-Week High
257.00CNY
NormalMar 18, 2026
52-Week Change
-39.48CNY
ExtremeMar 18, 2026
Beta
0.3050CNY
NormalMar 18, 2026
50-Day MA
189.54CNY
NormalMar 18, 2026
200-Day MA
214.22CNY
NormalMar 18, 2026
Avg 10-Day Volume
5.71MCNY
NormalMar 18, 2026
Avg 30-Day Volume
6.52MCNY
NormalMar 18, 2026
Diluted EPS (TTM)
7.11CNY
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.